Thyroid hormone receptor beta agonist may be safe, well tolerated in NASH

Thyroid hormone receptor beta agonist may be safe, well tolerated in NASH

Terns Pharmaceuticals announced positive top-line results from a phase 1 clinical trial of TERN-501, a thyroid hormone receptor beta agonist for the treatment of nonalcoholic steatohepatitis, according to a press release.“The goal of the phase 1 study is to evaluate the safety, tolerability pharmacodynamics and pharmacokinetics of TERN-501 in healthy volunteers,” D. Barry Crittenden, MD, MS, executive director of clinical research and medical affairs at Terns Pharmaceuticals, told Healio Gastroenterology. “We are very encouraged to see a positive phase 1 safety profileRead More

Share on facebook
Share on twitter
Share on linkedin